NEW
YORK, Aug. 28, 2024 /PRNewswire/
-- Immunic, Inc. (Nasdaq: IMUX), a
biotechnology company developing a clinical pipeline of orally
administered, small molecule therapies for chronic inflammatory and
autoimmune diseases, today announced that the company will host a
Multiple Sclerosis (MS) Research and Development (R&D) Day and
participate in the following scientific and investor conferences in
September:
- September 10: Immunic's MS
R&D Day. Management of Immunic, including Daniel Vitt, Ph.D., Chief Executive Officer;
Jason Tardio, M.B.A., Chief
Operating Officer and President; Andreas
Muehler, M.D., M.B.A., Chief Medical Officer; and
Hella Kohlhof, Ph.D., Chief
Scientific Officer, will be joined by two of the MS industry's
renowned experts to discuss the MS landscape as well as Immunic's
orally available lead-asset, nuclear receptor related 1 (Nurr1)
activator, vidofludimus calcium (IMU-838) and its potential to
become the treatment of choice for both relapsing and progressive
MS patients.
- Date: Tuesday, September 10,
2024
- Time: 10:30 am to 12:30 pm
ET, followed by a networking lunch
- Location: One Five One, 151 West 42nd Street,
New York, NY 10036
- Featured Experts:
- Francesca Montarolo, Ph.D., Neuroscience Institute Cavalieri
Ottolenghi (NICO) and University Hospital San Luigi Gonzaga of
Orbassano, Turin, Italy
- Amit Bar-Or, M.D., FRCPC, Melissa and Paul Anderson
Distinguished Chair, Director, Center for Neuroinflammation and
Experimental Therapeutics, Chief, Multiple Sclerosis Division,
Department of Neurology, Perelman School of Medicine, University of Pennsylvania
- To register, please RSVP by sending an email
to: ir@imux.com.
- September 18-20: 40th Congress
of the European Committee for Treatment and Research in Multiple
Sclerosis (ECTRIMS). Members of Immunic's management, medical,
clinical and preclinical teams will attend this conference in
Copenhagen, Denmark. Data on
vidofludimus calcium will be presented in an oral presentation and
three ePosters. Additionally, the team will be available throughout
the event at booth #60. All poster presentations will be accessible
on the "Events and Presentations" section of Immunic's website at:
https://ir.imux.com/events-and-presentations.
Oral Poster Presentation:
-
- Title: Serum Neurofilament Changes in Progressive MS:
Exploring the Impact of Vidofludimus Calcium by Age and Disability
in the CALLIPER Study Interim Analysis
- Presenting Author: Robert J.
Fox, Staff Neurologist, Mellon Center for Multiple
Sclerosis, Vice-Chair for Research, Neurological Institute,
Cleveland Clinic, Cleveland,
Ohio
- Poster Number: P753
- Session Title: Poster Session 2
- Session Date: Thursday, September
19, 2024
- Session Time: 4:45 pm –
6:45 pm CEST
ePosters:
-
- Title: Exploring the Potential of Vidofludimus
Calcium to Reduce Fatigue in Multiple Sclerosis by Preventing
Epstein-Barr Virus Reactivation
- ePoster Number: P1119
- Title: Vidofludimus Calcium Activity on NURR1 in
Preclinical Models: A Potential Neuroprotective Function in
Multiple Sclerosis
- ePoster Number: P1410
- Title: Vidofludimus Calcium Shows T Helper Cell
Modulatory Effects in Murine Experimental Autoimmune
Encephalomyelitis: One of the Potential Mode of Action Pathways for
MS Treatment
- ePoster Number: P1390
- September 2-4: DMDG
50th Open Meeting 2024. Juliano R. Fonseca, Ph.D., Head of Preclinical
Development at Immunic, will present data from Immunic's phase 1,
open-label mass balance and pharmacokinetics study of vidofludimus
calcium in a poster presentation at this meeting in York, United Kingdom.
- Title: Mass Balance and ADME Properties of
[14C]-IMU-838 Following Oral Administration to Healthy
Male Subjects
- The presentation and specific details regarding poster number
and session will be accessible on the "Events and Presentations"
section of Immunic's website at:
https://ir.imux.com/events-and-presentations, once they are
available.
- September 5-7: 20th
International Celiac Disease Symposium ICDS. Martina Wirth, Senior Manager Translational
Pharmacology at Immunic, will present data from Immunic's phase
1b clinical trial of IMU-856, an
orally available and systemically acting small molecule modulator
targeting SIRT6 (Sirtuin 6), in patients with celiac disease, in a
late-breaking poster presentation at this symposium in Sheffield, United Kingdom.
- Title: First-In-Human Trial of IMU-856, an Orally
Available Epigenetic Modulator of Barrier Function and Regeneration
for the Treatment of Celiac Disease
- The presentation and specific details regarding poster number
and session will be accessible on the "Events and Presentations"
section of Immunic's website at:
https://ir.imux.com/events-and-presentations, once they are
available.
- September 17-19: 2024 Cantor
Fitzgerald Global Healthcare Conference. Dr. Vitt will
participate in a fireside chat at this conference in New York on Wednesday,
September 18, 2024, at 3:05 pm
ET. A webcast of the presentation will be available on the
"Events and Presentations" section of Immunic's website
at: https://ir.imux.com/events-and-presentations. An archived
replay will be available on the company's website for a period of
90 days after the conference.
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing
a clinical pipeline of orally administered, small molecule
therapies for chronic inflammatory and autoimmune diseases. The
company's lead development program, vidofludimus calcium (IMU-838),
is currently in phase 3 and phase 2 clinical trials for the
treatment of relapsing and progressive multiple sclerosis,
respectively, and has shown therapeutic activity in phase 2
clinical trials in patients suffering from relapsing-remitting
multiple sclerosis, progressive multiple sclerosis and
moderate-to-severe ulcerative colitis. Vidofludimus calcium
combines neuroprotective effects, through its mechanism as a
first-in-class nuclear receptor related 1 (Nurr1) activator, with
additional anti-inflammatory and anti-viral effects, by selectively
inhibiting the enzyme dihydroorotate dehydrogenase (DHODH).
IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended
to restore intestinal barrier function and regenerate bowel
epithelium, which could potentially be applicable in numerous
gastrointestinal diseases, such as celiac disease, for which it is
currently in preparations for a phase 2 clinical trial. IMU-381,
which currently is in preclinical testing, is a next generation
molecule being developed to specifically address the needs of
gastrointestinal diseases. For further information, please visit:
www.imux.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains "forward-looking statements" that
involve substantial risks and uncertainties for purposes of the
safe harbor provided by the Private Securities Litigation Reform
Act of 1995. All statements, other than statements of historical
facts, included in this press release regarding strategy, future
operations, future financial position, future revenue, projected
expenses, sufficiency of cash and cash runway, expected
timing, development and results of clinical trials, prospects,
plans and objectives of management are forward-looking statements.
Examples of such statements include, but are not limited to,
statements relating to management's and employee's participation in
investor and scientific conferences. Immunic may not actually
achieve the plans, carry out the intentions or meet the
expectations or projections disclosed in the forward-looking
statements and you should not place undue reliance on these
forward-looking statements. Such statements are based on
management's current expectations and involve substantial risks and
uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements
as a result of many factors, including, without limitation, the
COVID-19 pandemic, increasing inflation, impacts of the
Ukraine – Russia conflict and the conflict in the
Middle East on planned and ongoing
clinical trials, risks and uncertainties associated with the
ability to project future cash utilization and reserves needed for
contingent future liabilities and business operations, the
availability of sufficient financial and other resources to meet
business objectives and operational requirements, the fact that the
results of earlier preclinical studies and clinical trials may not
be predictive of future clinical trial results, the protection and
market exclusivity provided by Immunic's intellectual property,
risks related to the drug development and the regulatory approval
process and the impact of competitive products and technological
changes. A further list and descriptions of these risks,
uncertainties and other factors can be found in the section
captioned "Risk Factors," in the company's Annual Report on Form
10-K for the fiscal year ended December 31,
2023, filed with the SEC on February
22, 2024, and in the company's subsequent filings with the
Securities and Exchange Commission. Copies of these filings are
available online at www.sec.gov or ir.imux.com/sec-filings. Any
forward-looking statement made in this release speaks only as of
the date of this release. Immunic disclaims any intent or
obligation to update these forward-looking statements to reflect
events or circumstances that exist after the date on which they
were made. Immunic expressly disclaims all liability in respect to
actions taken or not taken based on any or all the contents of this
press release.
Contact Information
Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com
US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
immunic@rxir.com
US Media Contact
KCSA Strategic Communications
Caitlin Kasunich
+1 212 896 1241
ckasunich@ksca.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/immunic-to-host-multiple-sclerosis-rd-day-and-participate-in-scientific-and-investor-conferences-in-september-302232141.html
SOURCE Immunic, Inc.